Information Provided By:
Fly News Breaks for October 12, 2018
LLY, ZTS, ELAN
Oct 12, 2018 | 08:42 EDT
Craig-Hallum analyst Kevin Ellich initiated Elanco Animal Health (ELAN) with a Hold rating and $33 price target. While Elanco is well positioned to expand gross margin by about 10 percentage points over the next five years which will drive mid-teens operating income growth and Ellich likes the company's focus on pet therapeutics and disease prevention as well as food animal future protein and health, he believes shares are fairly valued trading at ~19x FY20 EV/EBITDA, which is an 8% premium to industry leader Zoetis (ZTS). With shares up 35% from the September 19 IPO price of $24, the analyst tells investors in a research note that he looks to get more positive on pullbacks, improved liquidity as Eli Lilly (LLY) still owns 80% of Elanco stock, and improved visibility on longer-term growth drivers that could lead to upside to his projections.
News For ELAN;ZTS;LLY From the Last 2 Days
LLY
Mar 28, 2024 | 16:23 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
LLY
Mar 26, 2024 | 07:08 EDT
JPMorgan estimates Amgen (AMGN) without its obesity pipeline is worth $240-$250 per share and that the market is assigning $30-$40 per share of value to Maritide. While the competitive bar for Maritide is high and moving higher based on Novo Nordisk's (NVO) recent pipeline updates, the obesity market is also "unprecedented in terms of size," the analyst tells investors in a research note. The firm estimates peak sales for Maritide of $6B, equating to mid-single-digit share within the incretin space. JPMorgan believes this supports a value roughly in-line with what is reflected in Amgen's current share price. It sees a positive risk/reward scenario given the recent pullback but maintains a Neutral rating on the name with a $290 price target. The firm says Amgen is viewed as the best positioned name beyond Eli Lilly (LLY) and Novo to have a role in the obesity space.